Market Closed -
Hong Kong S.E.
01:38:20 14/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
1.2
HKD
|
+9.09%
|
|
+9.09%
|
-26.38%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
3,252
|
3,884
|
3,893
|
497.1
|
497.1
|
-
|
Enterprise Value (EV)
1 |
2,085
|
2,989
|
3,304
|
663
|
497.1
|
497.1
|
P/E ratio
|
-
|
-4.25
x
|
-3.44
x
|
-0.6
x
|
-0.62
x
|
-0.81
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
113
x
|
-
|
-
|
4.83
x
|
1.28
x
|
EV / Revenue
|
-
|
87.3
x
|
-
|
-
|
4.83
x
|
1.28
x
|
EV / EBITDA
|
-4.18
x
|
-3.61
x
|
-3.57
x
|
-0.64
x
|
-0.67
x
|
-0.94
x
|
EV / FCF
|
-4.6
x
|
-2.51
x
|
-3.34
x
|
-0.82
x
|
-0.6
x
|
-0.83
x
|
FCF Yield
|
-21.7%
|
-39.9%
|
-29.9%
|
-121%
|
-166%
|
-120%
|
Price to Book
|
1.81
x
|
2.16
x
|
2.19
x
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
3,69,390
|
3,87,590
|
4,47,500
|
4,47,500
|
4,47,500
|
-
|
Reference price
2 |
8.804
|
10.02
|
8.699
|
1.111
|
1.111
|
1.111
|
Announcement Date
|
26/03/21
|
25/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
-
|
34.23
|
-
|
-
|
103
|
388
|
EBITDA
1 |
-498.2
|
-828.9
|
-926.1
|
-1,040
|
-746
|
-529
|
EBIT
1 |
-504.9
|
-839.6
|
-944.5
|
-1,059
|
-741
|
-525
|
Operating Margin
|
-
|
-2,452.75%
|
-
|
-
|
-719.42%
|
-135.31%
|
Earnings before Tax (EBT)
1 |
-508.2
|
-842.1
|
-953.3
|
-1,069
|
-800
|
-615
|
Net income
1 |
-508.3
|
-842.1
|
-954.4
|
-1,061
|
-800
|
-615
|
Net margin
|
-
|
-2,460.04%
|
-
|
-
|
-776.7%
|
-158.51%
|
EPS
2 |
-
|
-2.360
|
-2.530
|
-2.470
|
-1.790
|
-1.380
|
Free Cash Flow
1 |
-452.8
|
-1,192
|
-988.7
|
-1,319
|
-824
|
-597
|
FCF margin
|
-
|
-3,483.15%
|
-
|
-
|
-800%
|
-153.87%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
26/03/21
|
25/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
589
|
-
|
-
|
Net Cash position
1 |
1,167
|
895
|
589
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-0.6611
x
|
-
|
-
|
Free Cash Flow
1 |
-453
|
-1,192
|
-989
|
-1,319
|
-824
|
-597
|
ROE (net income / shareholders' equity)
|
-54.1%
|
-50.9%
|
-54.5%
|
-56.3%
|
-53.5%
|
-41.1%
|
ROA (Net income/ Total Assets)
|
-42.3%
|
-41.1%
|
-
|
-51.4%
|
-48.5%
|
-36.5%
|
Assets
1 |
1,202
|
2,051
|
-
|
1,636
|
1,649
|
1,685
|
Book Value Per Share
|
4.870
|
4.640
|
3.970
|
-
|
-
|
-
|
Cash Flow per Share
|
-1.230
|
-2.950
|
-
|
-
|
-
|
-
|
Capex
1 |
69
|
76.2
|
27.5
|
222
|
91
|
91
|
Capex / Sales
|
-
|
222.61%
|
-
|
-
|
88.35%
|
23.45%
|
Announcement Date
|
26/03/21
|
25/03/22
|
30/03/23
|
28/03/24
|
-
|
-
|
Last Close Price
1.111
CNY Average target price
13.21
CNY Spread / Average Target +1,089.09% Consensus |
1st Jan change
|
Capi.
|
---|
| -26.38% | 63.01M | | +5.33% | 111B | | +12.11% | 105B | | -12.56% | 22.34B | | -3.70% | 21.93B | | -6.03% | 18.59B | | -35.21% | 18.12B | | -10.86% | 16.96B | | +5.10% | 13.7B | | +37.57% | 12.45B |
Bio Therapeutic Drugs
|